Roche Diagnostics' Test Determines Appropriate Pain-Relief Treatment For Nursing Mothers
Pain-Relief Treatment For Nursing Mothers
Nursing mothers with pain relief can be tested with Roche Diagnostics' AmpliChip CYP450 Test to help their doctors determine whether they are ultra-rapid metabolizers of codeine.
The Food & Drug Administration issued a Public Health Advisory on Friday warning nursing mothers about the potential negative effects of codeine while nursing.
Roche Diagnostics is the only company that makes an FDA-cleared test for determining a patients' CYP2D6 genotype, which helps a doctor predict how patients will metabolize certain drugs, including codeine.
The AmpliChip test analyzes variations in two genes -- CYP2D6 and CYP2C19 -- that play a primary role in the metabolism of some drugs used to treat severe depression, schizophrenia, bi-polar disorder, cardiovascular disease treated with beta-blockers, attention deficit/hyperactivity disorder (ADHD) and others.
Knowledge of these gene variations can be used to help individualize drug treatment through selection of the more appropriate drugs and adjustment of dosages. These measures have the potential to improve patient outcome by reducing adverse drug reactions and improving drug efficacy.